Welcome to MutualFunds.com. Please help us personalize your experience.
Thank you for your submission, we hope you enjoy your experience

Select the one that best describes you
Mutualfunds logo

FRBRX Franklin Biotechnology Discovery R6

  • Fund
  • FRBRX
  • Price as of: Aug 08, 2016
  • $144.15
  • - $1.45
  • - 1.00%
  • Category
  • Health & Biotech Equities

FRBRX - Profile

Vitals

  • YTD Return -13.9%
  • 3 Yr Annualized Return 10.7%
  • 5 Yr Annualized Return 20.7%
  • Net Assets $1.2 B
  • Holdings in Top 10 49.2%

52 WEEK LOW AND HIGH

$144.15
$117.61
$185.31

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.60%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 22.13%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$1,000,000

IRA

N/A

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return -13.9%
  • 3 Yr Annualized Total Return 10.7%
  • 5 Yr Annualized Total Return 20.7%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.17%
DIVIDENDS
  • Dividend Yield N/A
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name Franklin Biotechnology Discovery Fund
  • Fund Family Name Franklin Templeton Investments
  • Inception Date May 01, 2013
  • Shares Outstanding N/A
  • Share Class Retirement
  • Currency USD
  • Domiciled Country United States
  • Manager Evan S. McCulloch

FRBRX - Performance

Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -13.9% -25.2% 18.9% 87.50% 5
1 Yr -26.6% -29.1% 15.0% 93.75% 5
3 Yr 10.7% * 4.7% 22.2% 77.98% 4
5 Yr 20.7% * 10.5% 23.7% 17.14% 1
10 Yr 14.3% * 8.3% 16.3% 10.89% 1

* Annualized


Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%) Quintile
2015 -2.4% -20.4% 13.8% 53.21% 3
2014 N/A 13.1% 21.8% N/A N/A
2013 N/A 30.6% 65.2% N/A N/A
2012 N/A 9.6% 27.7% N/A N/A
2011 N/A -1.8% 18.0% N/A N/A

Total Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%) Quintile
YTD -13.9% -25.2% 18.9% 87.50% 5
1 Yr -26.6% -32.7% 15.0% 89.29% 5
3 Yr 10.7% * 3.2% 22.2% 76.15% 4
5 Yr 20.7% * 9.9% 23.7% 15.24% 1
10 Yr 14.3% * 8.0% 16.3% 8.91% 1

* Annualized


Total Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%) Quintile
2015 -2.4% -20.4% 13.8% 53.21% 3
2014 N/A 17.6% 22.2% N/A N/A
2013 N/A 51.1% 71.1% N/A N/A
2012 N/A 19.8% 39.6% N/A N/A
2011 N/A 13.8% 20.1% N/A N/A

NAV & Total Return History

FRBRX - Holdings

Filings data as of: Jun 30, 2016

Concentration Analysis

FRBRX Category Low Category High FRBRX % Rank Quintile
Net Assets 1.2 B 23.8 M 50.7 B 17.86% 3
Number of Holdings 124 30 356 7.14% 1
Net Assets in Top 10 592 M 9.08 M 20.2 B 18.75% 4
Weighting of Top 10 49.2% 22.2% 68.4% 7.14% 1

Top 10 Holdings

  1. Celgene Corp 9.46%
  2. Gilead Sciences Inc 7.80%
  3. Biogen Inc 7.10%
  4. Amgen Inc 5.88%
  5. Regeneron Pharmaceuticals Inc 3.29%
  6. Illumina Inc 2.36%
  7. Biomarin Pharmaceutical Inc 2.65%
  8. Incyte Corp 4.06%
  9. Medivation Inc 4.17%
  10. Vertex Pharmaceuticals Inc 2.46%

Asset Allocation

Weighting Category Low Category High FRBRX % Rank Quintile
Stocks
93.71% 87.51% 106.76% 30.36% 5
Cash
4.19% 0.00% 12.50% 4.46% 1
Other
2.10% -6.76% 2.31% 2.68% 1
Convertible Bonds
0.00% 0.00% 0.33% 3.57% 4
Preferred Stocks
0.00% 0.00% 1.48% 4.46% 4
Bonds
0.00% 0.00% 1.19% 3.57% 4

Stock Sector Breakdown

Weighting Category Low Category High FRBRX % Rank Quintile
Healthcare
93.71% 14.93% 99.47% 20.54% 3
Financial Services
0.00% 0.00% 1.13% 6.25% 4
Real Estate
0.00% 0.00% 1.99% 1.79% 4
Industrials
0.00% 0.00% 12.74% 15.18% 4
Utilities
0.00% 0.00% 1.25% 1.79% 4
Technology
0.00% 0.00% 64.47% 24.11% 5
Energy
0.00% 0.00% 0.00% 0.89% 4
Communication Services
0.00% 0.00% 2.23% 1.79% 4
Consumer Defense
0.00% 0.00% 2.38% 12.50% 4
Consumer Cyclical
0.00% 0.00% 4.23% 6.25% 4
Basic Materials
0.00% 0.00% 2.05% 3.57% 4

Stock Geographic Breakdown

Weighting Category Low Category High FRBRX % Rank Quintile
US
90.68% 62.67% 99.85% 13.39% 2
Non US
3.03% 0.14% 44.09% 30.36% 5

FRBRX - Expenses

Operational Fees

FRBRX Fees (% of AUM) Category Low Category High Rank in Category (%) Quintile
Expense Ratio 0.60% 0.10% 4.31% 66.96% 1
Management Fee 0.57% 0.08% 1.25% 16.07% 1
12b-1 Fee N/A 0.00% 1.00% N/A N/A
Administrative Fee 0.15% 0.01% 0.40% 6.15% 4

Sales Fees

FRBRX Fees (% of AUM) Category Low Category High FRBRX Rank Quintile
Front Load N/A 3.50% 5.75% N/A N/A
Deferred Load N/A 1.00% 5.00% N/A N/A

Trading Fees

FRBRX Fees (% of AUM) Category Low Category High FRBRX Rank Quintile
Max Redemption Fee N/A 0.75% 2.00% N/A N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FRBRX Fees (% of AUM) Category Low Category High FRBRX Rank Quintile
Turnover 22.13% 4.00% 249.00% 20.54% 1

FRBRX - Distributions

Dividend Yield Analysis

FRBRX Category Low Category High FRBRX % Rank Quintile
Dividend Yield N/A 0.01% 0.94% N/A N/A

Dividend Distribution Analysis

FRBRX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

FRBRX Category Low Category High FRBRX % Rank Quintile
Net Income Ratio -0.17% -2.26% 1.24% 23.21% 2

Capital Gain Distribution Analysis

FRBRX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

FRBRX - Managers

Evan S. McCulloch

Lead Manager

Start Date

Sep 15, 1997

Tenure

18.89

Tenure Rank

0.4%

Mr. McCulloch has been a portfolio manager of the Fund since 1997 and assumed duties of lead portfolio manager of the Fund in 2000. He has primary responsibility for the investments of the Fund. He has final authority over all aspects of the Fund's investment portfolio, including but not limited to, purchases and sales of individual securities, portfolio risk assessment, and the management of daily cash balances in accordance with anticipated cash management requirements. The degree to which he may perform these functions, and the nature of these functions, may change from time to time.


Steven Kornfeld

Manager

Start Date

Sep 15, 2015

Tenure

0.88

Tenure Rank

20.3%

Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.


Christopher Lee

Manager

Start Date

May 01, 2016

Tenure

0.25

Tenure Rank

22.5%

Christopher Lee is a vice president and research analyst with Franklin Equity Group. He covers biotechnology with a focus on oncology and emerging technologies such as genetherapy and RNA/DNA therapeutics. Prior research coverage includes the pharmaceutical, specialty pharma and medical technology sectors. Dr. Lee joined Franklin Templeton in 2015 and was previously with Capital Group. He has covered public and private healthcare companies since 2008 and began his career as a management consultant with McKinsey & Company. Dr. Lee received his M.D. from Columbia University and holds a B.S. in Molecular Biophysics & Biochemistry from Yale University.


Tenure Analysis

Category Low

0.1

Category High

18.9

Category Average

8.99

Category Mode

1.6